Remove Medicare Remove Peripheral Arterial Disease Remove Stenosis
article thumbnail

SCAI Scientific Sessions 2025 to Feature Presentations on TAVR, PAD and PE 

DAIC

Some of the late-breaking topics that will be covered include transcatheter aortic valve replacement (TAVR), peripheral artery disease (PAD), and pulmonary embolism (PE): Impact of Age on Procedural Timing for Asymptomatic Severe Aortic Stenosis: Results from the Early TAVR Trial The PERFORMANCE II Trial: A Prospective Multicenter Single Arm Investigation (..)

TAVR 52
article thumbnail

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

DAIC

1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. Journal of Vascular Surgery, Mar.

article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

We look forward to working with FDA, Centers for Medicare & Medicaid Services, and respective physician societies to bring this technology t­­o U.S. patients as soon as possible to elevate the standard of care for cardiovascular disease treatment.” vs. 8.7%; p=0.028) in the TLF rate with DynamX bioadaptor versus DES.

article thumbnail

Outpatient vascular care : Good, bad or ugly?

Dr. Anish Koka

Most have gotten used to egregiously bad coverage of current events that fills the pages of today’s New York Times, but even by their now very low standards a recent telling of a story about peripheral artery disease was very bad. These payments made him one of the highest paid vascular surgeons in the country.